{
  "abstract": "The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write Trudo Lemmens and colleagues",
  "authors": [
    {
      "affiliations": [
        "Faculty of Law, University of Toronto, Toronto, Canada",
        "Dalla Lana School of Public Health, University of Toronto, Toronto, Canada",
        "WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, University of Toronto, Toronto, Canada"
      ],
      "name": "Trudo Lemmens"
    },
    {
      "affiliations": [
        "Faculty of Law, University of Toronto, Toronto, Canada"
      ],
      "name": "Kanksha Mahadevia Ghimire"
    },
    {
      "affiliations": [
        "WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, University of Toronto, Toronto, Canada",
        "Faculty of Law, University of Amsterdam, Amsterdam, Netherlands"
      ],
      "name": "Katrina Perehudoff"
    },
    {
      "affiliations": [
        "WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, University of Toronto, Toronto, Canada",
        "Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada"
      ],
      "name": "Jillian Clare Kohler"
    },
    {
      "affiliations": [
        "Public representative, Eric Low Consulting, Haddington, Scotland"
      ],
      "name": "Eric Low"
    },
    {
      "affiliations": [
        "WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, University of Toronto, Toronto, Canada",
        "Faculty of Medicine, University of Toronto, Toronto, Canada"
      ],
      "name": "Navindra Persaud"
    }
  ],
  "title": "Pharmaceutical governance system for costly drugs through human rights due diligence",
  "uid": "752fe56c-41a8-53d0-b710-e503ea951fb1"
}